Stryker Corporation (NYSE:SYK)‘s stock had its “hold” rating reaffirmed by stock analysts at BMO Capital Markets in a report issued on Tuesday, July 11th. They currently have a $140.00 price objective on the medical technology company’s stock. BMO Capital Markets’ target price would indicate a potential downside of 4.46% from the company’s current price.

SYK has been the topic of several other reports. Goldman Sachs Group Inc began coverage on shares of Stryker Corporation in a report on Tuesday, May 16th. They issued a “neutral” rating and a $129.00 price objective on the stock. Cowen and Company set a $150.00 price target on shares of Stryker Corporation and gave the stock an “outperform” rating in a report on Wednesday, April 26th. Morgan Stanley increased their price target on shares of Stryker Corporation from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Monday, March 13th. Barclays PLC reissued a “sell” rating and set a $133.00 price target on shares of Stryker Corporation in a report on Thursday, April 27th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $132.00 price target on shares of Stryker Corporation in a report on Thursday, April 13th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $144.03.

Shares of Stryker Corporation (SYK) traded up 0.11% during trading on Tuesday, hitting $146.53. The stock had a trading volume of 638,405 shares. The stock has a 50 day moving average of $142.76 and a 200 day moving average of $134.44. The firm has a market cap of $54.81 billion, a PE ratio of 32.71 and a beta of 0.80. Stryker Corporation has a 52-week low of $106.48 and a 52-week high of $148.84.

Stryker Corporation (NYSE:SYK) last released its quarterly earnings data on Thursday, July 27th. The medical technology company reported $1.53 EPS for the quarter, beating the consensus estimate of $1.51 by $0.02. The business had revenue of $3.01 billion for the quarter, compared to the consensus estimate of $2.98 billion. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The business’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same period in the prior year, the firm earned $1.39 EPS. On average, equities analysts anticipate that Stryker Corporation will post $6.50 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Stryker Corporation (NYSE:SYK) Earns Hold Rating from BMO Capital Markets” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/08/07/stryker-co-nysesyk-given-hold-rating-at-bmo-capital-markets-updated-updated-updated.html.

In other Stryker Corporation news, insider David Floyd sold 19,305 shares of the stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $144.56, for a total transaction of $2,790,730.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. raised its position in shares of Stryker Corporation by 2,526.4% in the first quarter. BlackRock Inc. now owns 21,976,771 shares of the medical technology company’s stock valued at $2,893,242,000 after buying an additional 21,140,000 shares during the period. Vanguard Group Inc. raised its position in Stryker Corporation by 5.2% in the first quarter. Vanguard Group Inc. now owns 23,421,053 shares of the medical technology company’s stock valued at $3,083,382,000 after buying an additional 1,161,688 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Stryker Corporation by 41.9% in the first quarter. PNC Financial Services Group Inc. now owns 1,403,420 shares of the medical technology company’s stock valued at $184,759,000 after buying an additional 414,715 shares during the last quarter. SG Americas Securities LLC raised its position in Stryker Corporation by 600.6% in the first quarter. SG Americas Securities LLC now owns 412,340 shares of the medical technology company’s stock valued at $54,285,000 after buying an additional 353,486 shares during the last quarter. Finally, Morgan Stanley raised its position in Stryker Corporation by 17.9% in the first quarter. Morgan Stanley now owns 2,144,472 shares of the medical technology company’s stock valued at $282,320,000 after buying an additional 325,661 shares during the last quarter. 74.07% of the stock is owned by institutional investors.

About Stryker Corporation

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker Corporation (NYSE:SYK)

Receive News & Stock Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related stocks with our FREE daily email newsletter.